Displaying 1–25 of 242 results for Paul Thomas, Managing Editor

Sort By Relevance Sort By Date
1 2 3 4 5 ...10

Therapeutic Dose: The Scruffy Guy Cometh

(Article)

Director Michael Moore is pointing his lens toward the pharmaceutical industry, and drug company employees are on high alert. Love Moore or hate him, enjoy the limelight while it lasts, says Managing Editor Paul Thomas. Besides, an encounter might also be an opportunity to talk about the positive...

J&J Looks at Stable Isotopes for Process Analysis

(Article)

Stable isotopic analysis is already being used in pharmaceutical and raw material authentication, but spectrometry based on the technique promises to become a useful PAT tool. In this exclusive interview, John Jasper, CSO of Molecular Isotope Technologies, discusses the technology with Managing ...

The Good Fight: The Plight of Pharma's Middle Managers

(Article)

Middle managers in pharma today have a tough, thankless job—but someone’s got to do it, and many do it well.

Shoring Up Pharma’s Middle Management

(Article)

Organizations with built-in risk management frameworks allow middle managers to thrive, says Scott Chizzo, Maxiom Group’s president and chief consultant, in this exclusive interview.

Ode to the Code

(Article)

RFID can wait. Let’s watch barcoding come into its own, suggests Managing Editor Paul Thomas.

Therapeutic Dose: Canada and the Blame Game

(Article)

The drug importation issue: Stopping prescription drug shipments to online Canadian pharmacies only diverts attention from key safety and affordability issues, and a clear solution: track and trace technologies.

Chromatography Roundup

(Article)

While truly groundbreaking innovations in chromatography equipment happen every blue moon, there have been noteworthy gradual improvements in the areas of chromatography media, column packing and on-line buffer blending. Managing Editor Paul Thomas provides the big picture.

Is Your Diversity Diverse Enough?

(Article)

Managing Editor Paul Thomas discusses how hiring initiatives that focus on women and minorities may miss the big picture.

Therapeutic Dose: For a Pandemic, Call Out the Guard

(Article)

Managing Editor Paul Thomas discusses "big ideas" in flu pandemic preparedness, including a "national guard" for vaccine distribution.

Creative and Cautious: How Pharma’s Managers-Once-Removed Can Claim Relevance

(Article)

Industry consultant Jane Chin examines what makes the jobs of pharma’s middle managers so tough, and how they can succeed against the odds.

Condition Monitoring: Try Not To Be Alarmed

(Article)

With real-time, wireless and other new monitoring technologies, pharma gains better control of temperature, pressure, humidity, and more.

PharmaView: Where Everybody Knows Your Name

(Article)

If Ashton Kutcher were in pharma, he’d be on LinkedIn.

PharmaView: Pharma M&As: Been There, Done That?

(Article)

If the “serial acquirers” don’t kill us, they’ll make us stronger.

Onsite and Online, Interphex Attracting Visitors

(Article)

The annual spring tradeshow has reenergized itself by building a year-round online presence.

PharmaView: Should Pharma Fear the Supply Chain of the Future?

(Article)

As paradigms shift, we also need paradigm expansion.

The Need for New Models in Identifying New Molecules

(Article)

Probabilistic rather than deterministic modeling is essential, says Quintiles’ Davis Walp.

Inside GSK’s New RFID Pilot

(Article)

GlaxoSmithKline recently announced an item-level RFID pilot, and has begun tagging bottles of its Trizivir HIV medication, a common target for counterfeiting and diversion. GSK follows Pfizer (the "Little Blue Pill") and Purdue Pharma (Oxycontin) to detail item-level pilots. In this exclusive ...

PharmaView: What’s Your Saving Story?

(Article)

There’s nothing like a good tale of frugality to make your day.

PharmaView: Sell No Harm

(Article)

Makers of drugs for lethal injection face pressure to spurn U.S. prisons.

PharmaView: Are Unions (Love 'Em or Not) the Last Bastion for Pharma Job ...

(Article)

Communities can partner with manufacturers, but they can’t apply pressure.

PharmaView: Coming to America: European Companies Buy In and Lease

(Article)

"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.

Tales from the Middle

(Article)

Pharma's middle managers carry on despite a "damned if we do, damned if we don't" environment.

Big Steps, Shrinking Footprint at Novartis

(Article)

Novartis has made responsible energy usage part of its modus operandi, says Environment and Energy Manager Markus Lehni.

Temporary Workers: Pharma's Contingency Planning

(Article)

Consultant Steve Sawin answers our questions about managing contingent labor.

Eluding the OpEx Black Hole

(Article)

When it comes to operational excellence initiatives, middle managers are often seen as the problem—a black hole, if you will—but can be the solution.

Sort By Relevance Sort By Date
1 2 3 4 5 ...10